Organization (Nonprofit)
International AIDS Vaccine Initiative
ClinicalTrials.gov lists International AIDS Vaccine Initiative as lead sponsor of 37 trials. It has 24 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
This page covers International AIDS Vaccine Initiative: 37 lead-sponsored trials and 1 legal-entity registration.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 35 |
| Acquired Immunodeficiency Syndrome | 18 |
| Tuberculosis | 3 |
| Lassa Fever | 2 |
| Adenoviridae Infections | 1 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 21 years.
Prediction, not a registry value: median of 26 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 27 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (24)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| MTBVAC | Tuberculosis | Phase 2 | 2 |
| Day 1 Lower Dose (2×106 pfu) | Lassa Fever | Phase 2 | 1 |
| Day 1 Higher Dose (1×107 pfu) | Lassa Fever | Phase 2 | 1 |
| H56:IC31 | Recurrence | Phase 2 | 1 |
| H56:IC31 | Tuberculosis, Pulmonary | Phase 2 | 1 |
Showing 5 of 24 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 46% hit target (n=13) | 8% on time (n=13) |
Journals published in (24)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| PloS one | 12 |
| Nature medicine | 3 |
| The Journal of infectious diseases | 3 |
| The New England journal of medicine | 3 |
| AIDS research and human retroviruses | 2 |
Showing 5 of 24 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 69 | 25 | 2025-10-14 |
Financing and grant events (18)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | NIH grant | 3,358,279 | Reporter |
| 2025-06-23 | NIH grant | 700,469 | Reporter |
| 2024-09-30 | NIH grant | 2,268,333 | Reporter |
| 2024-09-30 | NIH grant | 680,601 | Reporter |
| 2024-04-16 | NIH grant | 448,768 | Reporter |
Showing 5 of 18 events.
Organization relationships (30)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| HIV Vaccine Trials Network | Co sponsors trial with | 3 |
| National Institute for Medical Research, Tanzania | Co sponsors trial with | 2 |
| Moderna, Inc. | Co sponsors trial with | 2 |
| US Military HIV Research Program | Co sponsors trial with | 2 |
| Targeted Genetics Corporation | Co sponsors trial with | 2 |
Showing 5 of 30 relationships.
Latest dated events (141)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 141 events.
Biomarker capability evidence (123)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 123 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.